Cyclacel Limited
LONDON, GB· latest recorded location
Cyclacel Limited is named on 56 US grants and 77 published applications in this corpus. Its most frequent classification is A61P (Therapeutic uses of medicines).
- Granted patents
- 56
- Published applications
- 77
- Inventors
- 114
- Granted in 2026 so far
- 0
- Most recent grant
- 23 Feb 2021
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 2 | 4 |
| 2003 | 4 | 7 |
| 2004 | 3 | 4 |
| 2005 | 5 | 13 |
| 2006 | 5 | 7 |
| 2007 | 4 | 3 |
| 2008 | 4 | 5 |
| 2009 | 4 | 8 |
| 2010 | 1 | 5 |
| 2011 | 2 | 3 |
| 2012 | 1 | 1 |
| 2013 | 7 | 3 |
| 2014 | 4 | 4 |
| 2015 | 3 | 4 |
| 2016 | 1 | 0 |
| 2017 | 2 | 0 |
| 2018 | 1 | 0 |
| 2019 | 1 | 2 |
| 2020 | 0 | 1 |
| 2021 | 1 | 0 |
| 2022 | 0 | 2 |
| 2023 | 0 | 1 |
By publication year.
Technology areas
Share of 133 documents
- A61PTherapeutic uses of medicines101
- A61KMedicines and medical preparations69
- C07DHeterocyclic compounds54
- Y02ATechnologies for adaptation to climate change20
- G01NInvestigating or analysing materials by determining their chemical or physical properties17
- C07KPeptides13
- C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms11
- C07BGeneral methods of organic chemistry7
- C07CAcyclic or carbocyclic compounds7
- C12NMicroorganisms or enzymes7
Recent patents
- Process for preparing purine derivatives23 Feb 2021US 10,927,113 B2
- Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia12 Mar 2019US 10,226,478 B2
- Dosage regimen for sapacitabine and seliciclib23 Jan 2018US 9,872,874 B2
- Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine13 Jun 2017US 9,675,631 B2
- Crystalline forms of a purine derivative21 Feb 2017US 9,573,951 B2
- Process for the preparation of purine derivatives exhibiting cdk inhibitory activity6 Apr 2023US 2023/0104823 A1
- Process for the preparation of a pyrimidino-diazepine derivative15 Sep 2022US 2022/0289755 A1
- Crystalline forms of pyrimidino diazepine derivative8 Sep 2022US 2022/0281880 A1
- Dosing regimen30 Apr 2020US 2020/0129509 A1
- Process for preparing purine derivatives26 Dec 2019US 2019/0389863 A1
Most cited
By later US patents
- Crystalline forms of a purine derivative99US 8,889,861 B22014
- Compositions and methods for monitoring the modification of modification dependent binding partner polypeptides87US 7,060,506 B22006
- Methods and compositions using protein binding partners51US 6,972,198 B22005
- Carrier based drug delivery system34US 6,472,507 B12002
- Anti-cancer compounds24US 6,531,479 B22003